Antihumoral rejection therapy by proteasome inhibitor bortezomib: a case series.
These three case reports strongly support previously published data on the usefulness of bortezomib as an innovative and potent antihumoral rejection therapeutical. Contrary to the current, conventional therapeutic regimens including rituximab, PPH and IVIg the administration of bortezomib led to significantly decreased DSA levels facilitating prolonged allograft survival in two out of three cases. The present data might also suggest that the time point of first administration of bortezomib as therapeutic agent is of high importance for the outcome since progressed graft deterioration due to long persisting DSA cannot be reversed.
Center for Tumor Medicine, HLA Laboratory, Charité- Universitätsmedizin Berlin, Berlin, Germany.
Nils
N
Lachmann
Manuela
M
Schütz
Klemens
K
Budde
Constanze
C
Schönemann
Johannes
J
Waiser
D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D003404:Creatinine / Q000097:blood; D005260:Female; D006084:Graft Rejection / Q000276:immunology* / Q000517:prevention & control*; D006681:HLA-D Antigens / Q000276:immunology; D015395:Histocompatibility Antigens Class I / Q000276:immunology; D006801:Humans; D056724:Immunity, Humoral; D016030:Kidney Transplantation / Q000276:immunology*; D019520:Living Donors; D008297:Male; D011480:Protease Inhibitors / Q000627:therapeutic use*; D011719:Pyrazines / Q000627:therapeutic use*; D006435:Renal Dialysis; D012086:Reoperation; D016896:Treatment Outcome
D001897:Boronic Acids; D006681:HLA-D Antigens; D015395:Histocompatibility Antigens Class I; D011480:Protease Inhibitors; D011719:Pyrazines; D000069286:Bortezomib; D003404:Creatinine